BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, January 16, 2026
Home » Newsletters » BioWorld MedTech

BioWorld MedTech

Jan. 5, 2021

View Archived Issues
Product image

Distalmotion wins CE mark for surgical robot

The medical device company Distalmotion SA has hit a regulatory milestone in the commercialization of its surgical robot, Dexter, earning a CE mark in Europe. The Dexter surgical robot is built with the aim of allowing surgeons to take a hybrid approach to minimally invasive surgery, using the robot for tasks such as suturing and complex dissections while switching to a laparoscopic approach for stapling and basic dissections. Read More
Brain and encephalography

Bioserenity scores win at FDA with solutions to remotely monitor people with epilepsy

Bioserenity SAS has gained U.S. FDA clearance for the Neuronaute electroencephalography (EEG) system and Icecap EEG wearable device, which aim to help physicians remotely monitor and assess electrical brain activity of people with epilepsy. The company noted that the Icecap and Neuronaute system will facilitate access to care in a variety of settings, including rural and remote environments. Read More
Regulatory-US-FDA-HQ.png

Little clarity over definition of ‘significantly’ in FDA’s STeP final guidance

The U.S. FDA’s safer technologies program, or STeP, is designed in part as a complement to the breakthrough devices program, but the September 2019 draft guidance lent little clarity as to what might constitute a significantly safer device. The Jan. 5, 2021, final guidance does little to clarify that question, however. Read More
Emboliner in glass arch

Emboline scoops up $10M in series C funding

Emboline Inc., which is developing technology to reduce the chance of stroke during transcatheter heart procedures, completed a $10 million series C financing. The funds are earmarked to gain initial commercial approval of the company’s Emboliner device and to launch a U.S. pivotal study. The round, which included new and existing investors, follows a $5 million bridge round of financing that closed last January. Read More
Inserting cartridge into Lightdeck

Brainbox heads into pivotal trial of concussion diagnostic test with $23M in new funding

A new $23 million in funds gives Brainbox Solutions Inc. a head start as it begins enrollment in the pivotal clinical trial of its mild traumatic brain injury (TBI) diagnostic and prognostic test. Bioventures Investors took the lead in the series A financing. The Tauber Foundation, the Virginia Tech Carilion Innovation and Seed Funds, Genoa VC, Pharmakon Holdings LLC, and Astia Angels participated in the fundraising round along with qualified investors including the Cleveland Cavaliers' Kevin Love, a mental health advocate. Read More

Appointments and advancements for Jan. 5, 2021

New hires and promotions in the med-tech industry, including: Biodesix, Biolife Solutions, Ceretrieve, Color, CS Analytical Laboratory, Cvrs, Inari Medical, Locate Bio, Novacyt, Tela Bio. Read More

Financings for Jan. 5, 2021

Med-tech firms raising money in public or private financings, including: Adapthealth, Canary Medical, Color, Pulse Biosciences, Viewray, Volta Medical. Read More

Other news to note for Jan. 5, 2021

Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Airstrip, Annar Health Technologies, Anthem, Aspen Laser Systems, Balt USA, Biotricity, Blue Earth Diagnostics, Bruker, Byte, Capsule Technologies, Coopersurgical, Curetis, Dentsply Sirona, Durect, Dxterity Diagnostics, Embryo Options, Emmes Company, Evonik, Evosep, Exact Sciences, Facedrive, Hanuman Pelican, Healthcore, Icecure Medical, Impulse Dynamics, Medx, Microvention, Neoteryx, Neox, Novamed, Nxt-ID, Nyxoah, Opgen, Ortho Regenerative Technologies, Perspectum, Premier, Protech, Redox, Retia Medical, Saphena, Scintomics, Sera Prognostics, Simplivia Healthcare, Terumo, Thrive Earlier Detection, Trice Imaging, University of Birmingham, Vibrent Health, Withings. Read More

Regulatory actions for Jan. 5, 2021

Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Accuray, Bioserenity, Nirmidas Biotech, Spark Biomedical, Trinity Biotech. Read More

Regulatory front for Jan. 5, 2021

The latest global regulatory news, changes and updates affecting medical devices and technologies, including: GAO says wound care spending dropped between 2016 and 2018; FDA updates COVID testing data; May 2019 Q-sub guidance appears in final form. Read More

BioWorld MedTech’s Oncology Extra for Jan. 5, 2021

Keeping you up to date on recent developments in oncology, including: Cellular ‘backpack’ boosts activity of macrophages against cancer; Hardware + software = slide-free histology; Researchers wary of social media for clinical trial recruitment; Peptides team up with nanowires to detect cancer exosomes. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 15, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 15, 2026.
  • SERPINB1 as potential biomarker for spinocerebellar ataxia type 2

    BioWorld Science
    Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
  • Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

    BioWorld
    With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
  • Businesswoman pressing dollar sign on touchscreen

    JPM 2026: Year kicks off with biopharma Q4 revenue and guidance

    BioWorld
    It was a battle of the companies with drugs for transthyretin-mediated amyloidosis on the first day of the J.P. Morgan 2026 Healthcare Conference with Alnylam...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing